Company registration number 09941789 (England and Wales)
KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022
KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
STRATEGIC REPORT
FOR THE YEAR ENDED 31 DECEMBER 2022
- 1 -

The directors present the strategic report for the year ended 31 December 2022.

Review of the business

The statement of financial position shows the company's financial position at the period end. The company's turnover for the period was £51,356,715 (31 December 2021: £45,286,646), The net assets as at 31 December 2022 were £19,153,946 (31 December 2021: £19,536,750).

 

Included within the profit and loss is an exceptional charge of £1,596,419 relating to impairment of software. The group continually strives to improves its software and processes to adapt to changing market conditions, costs associated with development have been capitalised under the Intangible asset Software.  The software has been developed over a number of years, however due to changing market conditions during 2022, it is difficult to value or give a useful life to the software.  Therefore, the Directors have impaired the carrying value of the asset to £Nil. This has resulted in the exceptional item .

 

The COVID-19 pandemic started to impact the company in early 2020.  National lockdowns in 2020 and 2021 created issues in supply chains and have extended case life cycles due to the availability of medical experts, medical records and court dates.

 

The introduction of the Official Injury Claim Portal in May 2021, has resulted in the total number of cases in the market reducing, however this has not had a significant negative impact on the performance of the company. The company has been impacted by the change in collection profiles, however the Directors believe that any change in collection profile in the short term will reverse in the long term, as the services provided support access to justice for individual claimants.

 

On the 8 March 2021 the group acquired Mobile Doctors Limited, therefore these Financial Statements represent the first full year of trade including Mobile Doctors Limited.

 

All of the above mean the results are not easily comparable to preceding years.

 

Given some of the challenges that have been faced over the last three years, the directors are satisfied with the performance of the company for the year ended 31 December 2022 and with its balance sheet position at this date.

 

Key performance indicators are disclosed below.

Principal Risks and Uncertainties

Legislative risk

The industry in which the group operates has been affected by uncertainty caused by the Chancellors announcement in the 2015 Autumn Statement that they will abolish general damages for 'minor' soft tissue claims which was proposed to include whiplash injuries. The reforms have been implemented in May 2021 and present both a risk and an opportunity to future volumes.

 

The Directors continue to review and consider the group's options and strategies to mitigate any potential negative impact and seek growth in other areas unaffected by the reforms.

 

Credit and cashflow risk

The group gives long credit terms to many of its customers. This is abrogated by reconciling regularly and issuing any credit notes promptly. The company monitors its short and middle term cash requirements and makes sure it has adequate funds to pay liabilities as they fall due. To offset the problems caused by the delays in cases within the Official Injury Claims Portal the group is actively looking to improve the ratio of short to long term credit.

 

Competitive risk

The industry in which the group operates is subject to strong competition from other providers. The group remains focused in providing the industry best service at a competitive price. Customer contracts generally extend past three years; both relationships and commercials are regularly reviewed to ensure contracts are the best value in the market.

KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022
- 2 -
Development and Performance

The industry in which the group operates is expected to change following the introduction of the Official Injury Claims Portal.  There has been a reduction in the total number of cases following implementation of the portal, although this has not had a significant negative impact on the performance of the group. There is currently uncertainty on the effect the portal will have on collection profiles, and this has an impact on group’s cash flows. The Directors remain of the opinion that any change in collection profile in the short term will reverse in the long term as the services provided support access to justice for individual claimants.

 

The group intends to consolidate its position in core markets to successfully manage any uncertainty caused by the reforms discussed, whilst exploring growth opportunities in adjacent markets.

Key performance Indicators

Key performance indicators used by the group were as follows:

 

 

 

 

 

 

 

31.12.2022

 

31.12.2021

 

 

 

 

as restated

Turnover

£'000

51,357

 

45,287

Gross margin

%

22.1

 

23.4

Profit After Tax (PAT)

£'000

(383)

 

1,187

PAT / Turnover

%

(0.7)

 

2.6

Net Assets

£'000

19,154

 

19,537

Average employees

No's

341

 

329

Receivable Collection

Days

342

 

329

 

 

 

 

 

S172 Statement

The directors of Kuro Health Limited are required to act in a way that they consider, in good faith, would be most likely to promote the success of the Company for the benefit of its members as a whole, and in so doing have regard, among other matters to:

To achieve their duties under Section 172 the directors pride themselves in ensuring that the Company is properly financed so that going concern should never be an issue. There is a fair dividend policy that ensures that the shareholders are adequately rewarded and the company retains sufficient profits to maintain a healthy balance sheet.

The directors/shareholders are involved in the day to day running of the business and have a team of managers who report regularly and meet on a monthly basis.

Good supplier relationships are fostered by the directors and managers and the Company ensures that suppliers are paid within their terms.

The Company strives to improve its standards which benefit its customers. The Company continually reviews financial information.

The directors produce three year plans to ensure the succession of the business, taking into account the local environment and communities in which their sites operate.

 

KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022
- 3 -

On behalf of the board

Dr H O Brunjes
Director
29 September 2023
KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2022
- 4 -

The directors present their annual report and financial statements for the year ended 31 December 2022.

Principal activities

The principal activity of the company is to act as the holding company for the group.

 

The group's principal activities are: the facilitation of non-invasive medical services, including patient screening, patient rehabilitation, medical reporting and diagnostic services for the personal injury claims market; and supply of computer consultancy services.

 

Results and dividends

The results for the year are set out on page 12.

 

 

 

No ordinary dividends were paid. The directors do not recommend payment of a final dividend.

Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

Dr H O Brunjes
Mr T Aspinall
Mrs J M Brunjes
Dr R Goodall
( Appointed 30 August 2022 and resigned 29 June 2023)
Mr B Gray
Mr G J Sampson
Mr J D Warner
Financial instruments

The group’s principal financial instruments comprise cash and cash equivalents, trade creditors and trade debtors. The main purpose of these instruments is to raise funds for the group’s operations. Due to the nature of these funds there is no exposure to price risk. There is a bank funding line from Barclays Bank PLC, this provides working capital and is secured against the assets of the group. A CBILS loan was taken out at the start of the pandemic.

 

Trade debtors are managed in respect of credit and cash flow risk by policies concerning the credit offered to customers and the regular monitoring of amounts outstanding and overdue. Trade creditors risk is managed by ensuring sufficient funds are available to meet amounts due.

Disabled persons

Applications for employment by disabled persons are always fully considered, bearing in mind the aptitudes of the applicant concerned. In the event of members of staff becoming disabled, every effort is made to ensure that their employment within the group continues and that the appropriate training is arranged. It is the policy of the group that the training, career development and promotion of disabled persons should, as far as possible, be identical to that of other employees.

Employee involvement

The group's policy is to consult and discuss with employees, through, staff councils, at meetings and online platforms, matters likely to affect employees' interests. Information about matters of concern to employees is given through information bulletins and reports which seek to achieve a common awareness on the part of all employees of the financial and economic factors affecting the group's performance.

KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022
- 5 -
Business relationships

An important part of the company's long term success is considered to be the need to regularly engage with all customers, potential customers and suppliers trying to match the needs of the customers and improving the service offered to them. This is achieved by seeking innovative ideas to improve service and to heed the request from suppliers for alternative methods to fulfil their contracts. During the pandemic the video assessment protocols have benefited all in the industry in the short term.

Future developments

The group's mid term strategy is to consolidate it's position post pandemic as a leading supplier of medical reports and related services by continually improving the solutions and services offered to customers.

Auditor

The auditor, Price Bailey LLP, is deemed to be reappointed under section 487(2) of the Companies Act 2006.

Energy and carbon report

Greenhouse Gas Emissions Data

In line with the Greenhouse Gas Protocol (GHG) Corporate Accounting and Reporting Standard, Kuro Health Limited continues to be engaged in a process aimed at reducing our energy and greenhouse gases, which is a response to increased customers’ requirements, as well as our belief in reducing emissions. This continues to be achieved by:

 

 

We have a longstanding commitment to tackling climate change. We have also committed to source 100% of our electricity from renewable sources by 2030.

 

Our emissions have reduced by 24.8%, which has been due to an increased awareness of our emissions and introducing better practices to manage it, as well as reducing our office space.

 

2022
2021
Energy consumption
kWh
kWh
Aggregate of energy consumption in the year
345,954
414,665
KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022
- 6 -
2022
2021
Emissions of CO2 equivalent
metric tonnes
metric tonnes
Scope 1 - direct emissions
- Gas combustion
29.45
36.00
- Fuel consumed for owned transport
-
-
29.45
36.00
Scope 2 - indirect emissions
- Electricity purchased
31.43
48.75
Scope 3 - other indirect emissions
- Fuel consumed for transport not owned by the
12.36
12.75
Total gross emissions
73.24
97.50
Intensity ratio
Tonnes C02e per metre squared
0.0434
0.0479
Quantification and reporting methodology

We have reported all of emission sources under the Companies Act 2006 (Strategic Report and Director’s Reports) Regulations 2013 as required. Kuro can report figures below, calculated based on the GHG Protocol Corporate Standard using emissions factors from UK government-produced conversion 2022 factor guidance. Reporting corresponds with our financial year and reflect emissions from the leased, owned, and controlled assets for which Kuro is responsible.

 

Kuro maintains scope one (1) and two (2) emissions, which are generated from our offices and processes. We also maintain scope three (3) emissions from transport covered under “grey fleet” (personal cars used for business purposes) and electricity transmission and distribution.

 

We have calculated and reported our emissions in line with the GHG Protocol Corporate Accounting and Reporting Standard (revised edition).

 

The reporting period is the fiscal year from 1 January 2022 to 31 December 2022, the same as that covered by the Annual Report and Financial Statements. The boundaries of the GHG inventory are defined using the financial control approach. In general, the emissions reported are the same as those which would be reported based on a financial control boundary.

 

Recorded energy consumption during the financial year was 345,954 (345.9 MWh).

Intensity measurement

The chosen intensity measurement ratio is total gross emissions in metric tonnes CO2e per metre squared, the recommended ratio for the sector.

Measures taken to improve energy efficiency

Kuro has been actively engaged in measures to reduce its energy throughout the reporting period as follows:

 

  1. Replaced T8 and inefficient lamps with low-energy LEDs in the kitchen areas.

  2. Installed passive infra-red (motions sensors) for all lighting.

  3. Continue to expand video conferencing and online meetings where possible.

KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022
- 7 -
Objectives

Update on objectives for prior year

In order to achieve the objectives set last year, the Group has implemented a new company car policy that includes leasing of electric vehicles and continued its strategy to reduce office space reducing its overall consumption of electricity.

 

Objectives for 2023

Kuro has initiated several objectives for the forthcoming fiscal year (to be reported on in the next set of accounts) as follows:

 

  1. Property strategy: review property strategy and reduce office footprint.

  2. Electric Vehicles: To continue to encourage employee to take up the new car policy.

  3. Behavioural Change: implementing a programme of educational and awareness of management team.

 

Kuro will report on progress in our next set of financial accounts.

Statement of disclosure to auditor

So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information, being information needed by the auditor on connection with preparing its report, of which the auditor is unaware. Having made enquiries of fellow directors and the group's auditor, each director has taken all the steps that he / she is obliged to take as a director in order to make himself / herself aware of any relevant audit information, and to establish that the auditor is aware of that information.

On behalf of the board
Dr H O Brunjes
Director
29 September 2023
KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
DIRECTORS' RESPONSIBILITIES STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2022
- 8 -

The directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and regulations.

 

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the group and company, and of the profit or loss of the group for that period. In preparing these financial statements, the directors are required to:

 

 

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the group’s and company’s transactions and disclose with reasonable accuracy at any time the financial position of the group and company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the group and company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
- 9 -
Opinion

We have audited the financial statements of Kuro Health Limited (the 'parent Company') and its subsidiaries (the 'Group') for the year ended 31 December 2022, which comprise the Consolidated Statement of Comprehensive Income, the Consolidated and Company Balance Sheets, the Consolidated and Company Statement of Changes in Equity, the Consolidated Statement of Cash Flows and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

 

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the Group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Group's or the parent Company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

 

Our responsibilities and the responsibilities of the Directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the Annual Report other than the financial statements and our Auditors' Report thereon. The Directors are responsible for the other information contained within the Annual Report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

 

We have nothing to report in this regard.

KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
- 10 -

Opinion on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

 

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the Group and the parent Company and its environment obtained in the course of the audit, we have not identified material misstatements in the Group Strategic Report or the Directors' Report.

 

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

 

Responsibilities of directors

As explained more fully in the Directors' Responsibilities Statement, the Directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

 

In preparing the financial statements, the Directors are responsible for assessing the Group's and the parent Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Directors either intend to liquidate the Group or the parent Company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors' Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Group financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

We gained an understanding of the legal and regulatory framework applicable to the group and the industries in which it operates and considered the risk of the group and company not complying with the applicable laws and regulations including fraud in particular those that could have a material impact on the financial statements. This included those regulations directly related to the financial statements, including financial reporting, tax legislation and distributable profits. In relation to the industry, this included consideration of the Medco status of various members of the group, employment law and health & safety. The risks were discussed with the audit team and we remained alert to any indications of non-compliance throughout the audit.

KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
- 11 -

The risks were discussed with the audit team and we remained alert to any indications of non-compliance throughout the audit. We carried out specific procedures to address the risks identified. As follows:

 

To address the risk of management override of controls, we reviewed systems and procedures to identify potential areas of management override risk. In particular, we carried out testing of journal entries and other adjustments for appropriateness, and evaluating the business rationale of significant transactions to identify large or unusual transactions. We reviewed key authorisation procedures and decision-making processes for any unusual or one-off transactions. We also assessed management bias in relation to the accounting policies adopted and in determining significant accounting estimates.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our Auditors' Report.

Use of our report

This report is made solely to the Company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Company's members those matters we are required to state to them in an Auditors' Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's members, as a body, for our audit work, for this report, or for the opinions we have formed.

Darren Amott (Senior Statutory Auditor)
For and on behalf of Price Bailey LLP
29 September 2023
Chartered Accountants
3rd Floor, 24 Old Bond Street
Statutory Auditors
London
W1S 4AP
KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 DECEMBER 2022
- 12 -
2022
2021
as restated
Notes
£
£
Turnover
3
51,356,715
45,286,646
Cost of sales
(40,001,435)
(34,690,622)
Gross profit
11,355,280
10,596,024
Administrative expenses
(9,324,976)
(8,873,495)
Other operating income
3
716
103,454
Operating profit
4
2,031,020
1,825,983
Interest receivable and similar income
8
161
97
Interest payable and similar expenses
9
(818,360)
(459,742)
Impairment on other intangible assets
11
(1,596,419)
-
0
(Loss)/profit before taxation
(383,598)
1,366,338
Tax on (loss)/profit
10
794
(179,809)
(Loss)/profit for the financial year
(382,804)
1,186,529
(Loss)/profit for the financial year is all attributable to the owners of the parent company.
Total comprehensive income for the year is all attributable to the owners of the parent company,

The profit and loss account has been prepared on the basis that all operations are continuing operations.

KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
CONSOLIDATED BALANCE SHEET
AS AT
31 DECEMBER 2022
31 December 2022
- 13 -
2022
2021
as restated
Notes
£
£
£
£
Fixed assets
Goodwill
13
2,001,249
2,357,696
Other intangible assets
13
139,597
1,822,657
Total intangible assets
2,140,846
4,180,353
Tangible assets
12
410,251
544,941
2,551,097
4,725,294
Current assets
Debtors
16
61,794,162
52,427,447
Cash at bank and in hand
272,455
895,104
62,066,617
53,322,551
Creditors: amounts falling due within one year
17
(42,649,932)
(35,451,995)
Net current assets
19,416,685
17,870,556
Total assets less current liabilities
21,967,782
22,595,850
Creditors: amounts falling due after more than one year
18
(2,635,336)
(2,750,000)
Provisions for liabilities
20
(178,500)
(309,100)
Net assets
19,153,946
19,536,750
Capital and reserves
Called up share capital
23
2,037
2,037
Capital redemption reserve
463
463
Profit and loss reserves
19,151,446
19,534,250
Total equity
19,153,946
19,536,750
The financial statements were approved by the board of directors and authorised for issue on 29 September 2023 and are signed on its behalf by:
29 September 2023
Dr H O Brunjes
Director
Company Registration No. 09941789
KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
COMPANY BALANCE SHEET
AS AT 31 DECEMBER 2022
31 December 2022
- 14 -
2022
2021
Notes
£
£
£
£
Fixed assets
Investments
14
6,550,364
6,597,894
Current assets
Debtors
16
10,368,543
10,249,654
Cash at bank and in hand
11,562
7,392
10,380,105
10,257,046
Creditors: amounts falling due within one year
17
(2,318,684)
(1,396,187)
Net current assets
8,061,421
8,860,859
Total assets less current liabilities
14,611,785
15,458,753
Creditors: amounts falling due after more than one year
18
(1,175,000)
(1,175,000)
Net assets
13,436,785
14,283,753
Capital and reserves
Called up share capital
23
2,037
2,037
Capital redemption reserve
463
463
Profit and loss reserves
13,434,285
14,281,253
Total equity
13,436,785
14,283,753

 

The financial statements were approved by the board of directors and authorised for issue on 29 September 2023 and are signed on its behalf by:
29 September 2023
Dr H O Brunjes
Director
Company registration number 09941789 (England and Wales)
KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
GROUP STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2022
- 15 -
Share capital
Capital redemption reserve
Profit and loss reserves
Total
£
£
£
£
Balance at 1 January 2021
2,037
463
18,347,721
18,350,221
Period ended 31 December 2021:
Profit and total comprehensive income
-
-
1,186,529
1,186,529
Balance at 31 December 2021
2,037
463
19,534,250
19,536,750
Year ended 31 December 2022:
Loss and total comprehensive income
-
-
(382,804)
(382,804)
Balance at 31 December 2022
2,037
463
19,151,446
19,153,946
KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
COMPANY STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2022
- 16 -
Share capital
Capital redemption reserve
Profit and loss reserves
Total
£
£
£
£
Balance at 1 January 2021
2,037
463
14,425,104
14,427,604
Period ended 31 December 2021:
Loss and total comprehensive income for the period
-
-
(143,851)
(143,851)
Balance at 31 December 2021
2,037
463
14,281,253
14,283,753
Year ended 31 December 2022:
Loss and total comprehensive income for the year
-
-
(846,968)
(846,968)
Balance at 31 December 2022
2,037
463
13,434,285
13,436,785
KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
GROUP STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2022
- 17 -
2022
2021
Notes
£
£
£
£
Cash flows from operating activities
Cash absorbed by operations
26
(1,752,120)
(2,233,271)
Corporation tax paid
3,644
(277)
Net cash outflow from operating activities
(1,748,476)
(2,233,548)
Investing activities
Purchase of intangible assets
(378,629)
(425,363)
Purchase of tangible fixed assets
(72,376)
(179,629)
Proceeds from disposal of tangible fixed assets
601
-
Purchase of subsidiaries
-
(1,109,940)
Interest received
161
97
Net cash used in investing activities
(450,243)
(1,714,835)
Financing activities
Repayment of borrowings
(126,563)
(2,975,000)
New loan
630,574
-
Interest paid
(818,360)
(459,742)
Net cash used in financing activities
(314,349)
(3,434,742)
Net decrease in cash and cash equivalents
(2,513,068)
(7,383,125)
Cash and cash equivalents at beginning of year
(12,153,001)
(4,769,876)
Cash and cash equivalents at end of year
(14,666,069)
(12,153,001)
Relating to:
Cash at bank and in hand
272,455
895,104
Bank overdrafts included in creditors payable within one year
(14,938,524)
(13,048,105)
KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022
- 18 -
1
Accounting policies
Company information

Kuro Health Limited ("the company") is a private limited company domiciled and incorporated in England and Wales and limited by shares. The registered office is 4th Floor, Park Gate, 161-163 Preston Road, Brighton, East Sussex, BN1 6AF.

 

The group consists of Kuro Health Limited and all of its subsidiaries.

 

The group's consolidated and the company's financial statements have been prepared in compliance with FRS102 as it applies to the financial statements for the year ended 31 December 2022.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

Basis of preparation for the company

The company is a qualifying entity for the purposes of FRS 102, being a member of a group where the parent of that group prepares publicly available consolidated financial statements, including this company, which are intended to give a true and fair view of the assets, liabilities, financial position and profit or loss of the group. The company has therefore taken advantage of exemptions from the following disclosure requirements:

 

 

The consolidated financial statements of the group include the results of the company. Consequently, as permitted by s408 of the Companies Act 2006, no individual company income statement is presented in these financial statements for Kuro Health Limited.

The principal accounting policies adopted are set out below.

1.2
Basis of consolidation

In the parent company financial statements, the cost of a business combination is the fair value at the acquisition date of the assets given, equity instruments issued and liabilities incurred or assumed, plus costs directly attributable to the business combination. The excess of the cost of a business combination over the fair value of the identifiable assets, liabilities and contingent liabilities acquired is recognised as goodwill. The cost of the combination includes the estimated amount of contingent consideration that is probable and can be measured reliably, and is adjusted for changes in contingent consideration after the acquisition date. Provisional fair values recognised for business combinations in previous periods are adjusted retrospectively for final fair values determined in the 12 months following the acquisition date. Investments in subsidiaries are accounted for at cost less impairment.

KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022
1
Accounting policies
(Continued)
- 19 -

The consolidated financial statements incorporate those of Kuro Health Limited and all of its subsidiaries (ie entities that the group controls through its power to govern the financial and operating policies so as to obtain economic benefits). Subsidiaries acquired during the period are consolidated using the purchase method. Their results are incorporated from the date that control passes.

 

All financial statements are made up to 31 December 2022. Where necessary, adjustments are made to the financial statements of subsidiaries to bring the accounting policies used into line with those used by other members of the group.

 

All intra-group transactions, balances and unrealised gains on transactions between group companies are eliminated on consolidation. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred.

1.3
Going concern

The financial statements have been prepared on a going concern basis. Forecasts have been prepared that show the Group will have sufficient liquidity to meet its financial obligations for a period of at least 12 months from the date of this financial report. 

 

This assessment undertaken by the Directors has been predominantly considered from a cash-flow perspective, as the group operating profit remains positive and with a strong balance sheet £19m shareholders funds. The Directors have considered the implications of current rates of inflation and wider market conditions. To ensure the Business continues to operate as a going concern, the Group continually monitor the longer-term impacts of the pandemic on key stakeholders caused by issues such as court delays and availability of medical experts, which have extended case life cycles.

 

The Directors have also considered the impact of the Official Injury Claims portal, implemented on the 31st May 2021. The Directors monitor both internal and external key performance indicators for the work generated via the new portal, including volume of cases, instructions received and case cycle times. However, case cycle times have extended and there is uncertainty when collection profiles will return to pre OIC portal levels. This has an impact on Group’s cash flows. The Directors remain of the opinion that any change in collection profile in the short term will reverse in the long term as the services provided support access to justice for individual claimants. However, there remains a level of uncertainty around collections, due to limited number of cases that have settled during the first two years of operation for the new portal.

 

The Directors have implemented a number of strategies to mitigate the impact of the change in collection profiles discussed above. These strategies include a review of all commercial arrangements, operational processes and associated costs and have the aim to reduce the working capital requirements of the Group in both short term and long term.

 

The Group have a long-term and close working relationship with its bankers. The Group’s facilities have been renegotiated during the year with a temporary increase invoice discounting facility, as well as drawing on other short-term finance that has been made available. Facilities have been agreed until August 2024 at a level consistent with forecasted requirements. The Group and the shareholders have confirmed they will support the working capital requirements if necessary via loans and personal guarantees.

 

The Directors have prepared forecasts for a period of more than 12 months from the date of approval of these financial statements and are confident that the sources of funding available, together with the mitigation strategies that are in place, will provide sufficient liquidity until the issues with the Official Injury Claims Portal are resolved.

 

The Group is well funded and capitalised, and despite the uncertainty above, the Directors believe that it is appropriate to prepare the accounts on a going concern basis.

 

KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022
1
Accounting policies
(Continued)
- 20 -
1.4
Turnover

Turnover is recorded at the fair value of the consideration receivable in the normal course of business, net of VAT, other sales related taxes and discounts.The group provides services in the medical legal sector and the IT software sector.

Medical work is contracted for delivery over an agreed period, typically ending at the settlement of the legal medical claim. Requests for payments are issued at predetermined points in the process according to contract and are recorded as turnover. At the balance sheet date, the company accrues for turnover in respect of services performed but un-invoiced, accrued income is included within other debtors. Any associated expected costs of services provided are accrued and included in other creditors.

IT software services are contracted for delivery over an agreed period. Requests for payments are issued at predetermined points in the process according to contract and are recorded as turnover. At the balance sheet date, the company accrues for turnover in respect of services performed but un-invoiced, accrued income is included within other debtors. Any associated expected costs of services provided are accrued and included in other creditors.

1.5
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of a business over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

 

Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is ten years.

1.6
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

 

Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following basis:

Software
5 years straight line
Customer contracts
5 years straight line
Licences
Indefinite useful life
1.7
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold external improvements
20%    straight line
Leasehold internal improvements
33.3% straight line
Fixtures & fittings
20%    straight line
Computer equipment
20%    straight line

Assets in the course of construction are not depreciated.

KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022
1
Accounting policies
(Continued)
- 21 -

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the profit and loss account.

1.8
Fixed asset investments

In the parent company financial statements, investments in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses.

A subsidiary is an entity controlled by the group. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

1.9
Impairment of fixed assets

At each reporting period end date, the group reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

 

The carrying amount of the investments accounted for using the equity method is tested for impairment as a single asset. Any goodwill included in the carrying amount of the investment is not tested separately for impairment.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.10
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022
1
Accounting policies
(Continued)
- 22 -
1.11
Financial instruments

The group has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the group's balance sheet when the group becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset and the net amounts presented in the financial statements when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Other financial assets

Other financial assets, including investments in equity instruments which are not subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the transaction price. Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are measured at cost less impairment.

Impairment of financial assets

Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.

 

Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.

 

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

Derecognition of financial assets

Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the group transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the group after deducting all of its liabilities.

KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022
1
Accounting policies
(Continued)
- 23 -
Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Derecognition of financial liabilities

Financial liabilities are derecognised when the group's contractual obligations expire or are discharged or cancelled.

1.12
Equity instruments

Equity instruments issued by the group are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the group.

1.13
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the period. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The group’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset if, and only if, there is a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.14
Provisions

Provisions are recognised when the group has a legal or constructive present obligation as a result of a past event, it is probable that the group will be required to settle that obligation and a reliable estimate can be made of the amount of the obligation.

 

The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the reporting end date, taking into account the risks and uncertainties surrounding the obligation. Where the effect of the time value of money is material, the amount expected to be required to settle the obligation is recognised at present value. When a provision is measured at present value, the unwinding of the discount is recognised as a finance cost in profit or loss in the period in which it arises.

KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022
1
Accounting policies
(Continued)
- 24 -
1.15
Employee benefits

The company operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the company in an independently administered fund. Payments to the defined contribution scheme are charged as an expense as they fall due.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.16
Retirement benefits

The group operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the company in an independently administered fund. Payments to the defined contribution scheme are charged as an expense as they fall due.

1.17
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leased asset are consumed.

1.18
Government grants

The group is using the accrual model to account for government grants. Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received. Relevant grants in this period are:

 

Government grants relating to the 'Coronavirus Job Retention Scheme' are recognised as income over the periods when the related costs are incurred.

 

Government grants relating to the settlement of interest and lender-levied charges relating to the Coronavirus Business Interruption Loan Scheme are recognised as income in the period in which the related costs are incurred.

1.19
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2
Judgements and key sources of estimation uncertainty

In the application of the group’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022
2
Judgements and key sources of estimation uncertainty
(Continued)
- 25 -
Key sources of estimation uncertainty

The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are as follows.

Credit note provision

Revenue from services are recognised on accordance with the policy set out at 1.4 on the expectation that most cases will be successfully concluded. Cases on average complete within two years however there are instances where cases are unsuccessful, and fees are not recoverable. 

As a consequence, an element of judgement is required to account for potential fluctuations in income. A provision for credit notes is utilised to estimate the potential impact of such changes to case profiles and the respective incomes. The provision is calculated based on historical experience, current trends, industry knowledge and other relevant factors. The judgements used to calculate the provision, are material to the results of the company. A small change in those judgements could have a relatively significant impact on the accounts. Therefore the results of the company are sensitive to movements in this provision if assumptions and trends change.

 

The senior management team have adequate controls and KPIs in place to monitor and assess the suitability of the provision to ensure income is fairly stated in the financial statements.

Investment Cost

Investment in subsidiaries are recognised in accordance with the policy set out at 1.8 on the expectation that costs are contractually payable. However, there are instances where costs payable are deferred and payable based on future contract performance.

Consequently, an element of judgement is required to account for potential fluctuations in cost of investments.  The provision is calculated based on historical experience, current trends, industry knowledge and other relevant factors.  A change in those judgements and future performance could have an impact on the accounts.  Therefore, the balance sheet of the company is sensitive to movements in this provision if assumptions and future performance.

 

The senior management team have adequate controls and KPIs in place to monitor and assess the suitability of the assessment to ensure income and investment cost are fairly stated in the financial statements.

 

 

 

 

 

 

 

KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022
- 26 -
3
Turnover and other revenue

An analysis of the group's turnover is as follows:

2022
2021
as restated
£
£
Turnover analysed by class of business
Medical reporting services
49,130,529
43,080,784
Computer consultancy
2,226,186
2,205,862
51,356,715
45,286,646
2022
2021
£
£
Other significant revenue
Interest income
161
97
Grants received
716
103,454
2022
2021
as restated
£
£
Turnover analysed by geographical market
United Kingdom
50,874,494
44,810,170
Europe
462,385
476,476
Rest of World
19,836
-
51,356,715
45,286,646

All turnover derives from services rendered and from continuing operations.

4
Operating profit
2022
2021
£
£
Operating profit for the year is stated after charging/(crediting):
Exchange (gains)/losses
(171)
14,103
Government grants
(716)
(103,454)
Depreciation of owned tangible fixed assets
177,997
189,744
Impairment of owned tangible fixed assets
28,468
-
Amortisation of intangible assets
534,193
819,813
Operating lease charges
413,144
354,011
KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022
- 27 -
5
Auditor's remuneration
2022
2021
Fees payable to the company's auditor and associates:
£
£
For audit services
Audit of the financial statements of the group and company
17,250
12,825
Audit of the financial statements of the company's subsidiaries
136,994
91,300
154,244
104,125
6
Employees

The average monthly number of persons (including directors) employed by the group and company during the year was:

Group
Company
2022
2021
2022
2021
Number
Number
Number
Number
Developer
-
6
-
-
Administration
42
47
7
6
Operations
296
274
-
-
Sales
3
2
-
-
Total
341
329
7
6

Their aggregate remuneration comprised:

Group
Company
2022
2021
2022
2021
£
£
£
£
Wages and salaries
10,107,528
8,982,898
704,590
580,672
Social security costs
1,000,419
825,586
91,684
70,120
Pension costs
459,452
407,790
22,142
20,714
11,567,399
10,216,274
818,416
671,506

 

 

 

 

 

 

KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022
- 28 -
7
Directors' remuneration
2022
2021
£
£
Remuneration for qualifying services
662,493
577,435
Company pension contributions to defined contribution schemes
22,142
20,714
684,635
598,149
Remuneration disclosed above includes the following amounts paid to the highest paid director:
2022
2021
£
£
Remuneration for qualifying services
243,021
228,851
Company pension contributions to defined contribution schemes
12,541
11,782

The number of directors the company pension contributions relates to in the period under review is 2 (2021: 2).

 

Directors of the business are deemed to be key management and have been remunerated accordingly.

8
Interest receivable and similar income
2022
2021
£
£
Interest income
Interest on bank deposits
100
97
Other interest income
61
-
Total income
161
97
9
Interest payable and similar expenses
2022
2021
£
£
Interest on bank overdrafts and loans
668,913
311,436
Dividends on redeemable preference shares not classified as equity
141,000
141,000
Interest on finance leases and hire purchase contracts
-
7,306
Other interest
8,447
-
Total finance costs
818,360
459,742
KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022
- 29 -
10
Taxation
2022
2021
£
£
Current tax
UK corporation tax on profits for the current period
43,543
296,968
Adjustments in respect of prior periods
-
0
(196,713)
Total current tax
43,543
100,255
Deferred tax
Origination and reversal of timing differences
(44,337)
76,154
Adjustment in respect of prior periods
-
0
3,400
Total deferred tax
(44,337)
79,554
Total tax (credit)/charge
(794)
179,809

The actual (credit)/charge for the year can be reconciled to the expected (credit)/charge for the year based on the profit or loss and the standard rate of tax as follows:

2022
2021
£
£
(Loss)/profit before taxation
(383,598)
1,366,338
Expected tax (credit)/charge based on the standard rate of corporation tax in the UK of 19.00% (2021: 19.00%)
(72,884)
259,604
Tax effect of expenses that are not deductible in determining taxable profit
80,716
29,528
Tax effect of utilisation of tax losses not previously recognised
-
0
(19,624)
Adjustments in respect of prior years
-
0
(196,713)
Permanent capital allowances in excess of depreciation
16,787
(66,359)
Amortisation on assets not qualifying for tax allowances
-
0
152,254
Research and development tax credit
-
0
(47,778)
Other permanent differences
32,376
(7,317)
Movement in deferred tax asset
(44,337)
79,554
Utilisation of provisions
(18,975)
(3,306)
Effect of Profit/(Loss) on fixed asset disposal
113
(34)
Impairment losses
5,410
-
Taxation (credit)/charge
(794)
179,809

Future tax rate changes

 

In the Budget, the Chancellor announced that corporation tax rates would increase to 25% from 1 April 2023. The rate used for calculating deferred tax is the 25% (2021: 19%).

 

KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022
- 30 -
11
Impairments

Impairment tests have been carried out where appropriate and the following impairment losses have been recognised in profit or loss:

2022
2021
Notes
£
£
In respect of:
Intangible assets
13
1,766,818
-
Property, plant and equipment
12
28,468
-
Recognised in:
Administrative expenses
198,867
-
Impairment adjustments
1,596,419
-

The impairment losses in respect of financial assets are recognised in other gains and losses in the profit and loss account.

The group continually strives to improves its software and processes to adapt to changing market conditions, costs associated with development have been capitalised under the Intangible asset Software.  The software has been developed over a number of years, however due to changing market conditions during 2022, it is difficult to value or give a useful life to the software.  Therefore, the Directors have impaired the carrying value of the asset to £Nil. This has resulted in a charge to the Profit & Loss account of £1,596,419, which has been presented as an exceptional item.

During the year the group impaired property plant and equipment assets linked to an office where a break notice has been served during the year, therefore the useful life has been reduced.

Included above in respect of intangible assets is £170,399. This is the revaluation of an investment included in note 13.

 

 

KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022
- 31 -
12
Tangible fixed assets
Group
Leasehold internal improvements
Fixtures & fittings
Computer equipment
Total
£
£
£
£
Cost
At 1 January 2022
142,916
184,773
945,588
1,273,277
Additions
7,300
-
0
65,076
72,376
Disposals
-
0
(13,461)
(556,048)
(569,509)
At 31 December 2022
150,216
171,312
454,616
776,144
Depreciation and impairment
At 1 January 2022
84,678
68,852
574,806
728,336
Depreciation charged in the year
36,162
17,399
124,436
177,997
Impairment losses
13,395
15,073
-
0
28,468
Eliminated in respect of disposals
-
0
(12,866)
(556,042)
(568,908)
At 31 December 2022
134,235
88,458
143,200
365,893
Carrying amount
At 31 December 2022
15,981
82,854
311,416
410,251
At 31 December 2021
58,238
115,921
370,782
544,941
The company had no tangible fixed assets at 31 December 2022 or 31 December 2021.

More information on impairment movements in the year is given in note 11.

 

 

 

 

 

 

 

KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022
- 32 -
13
Intangible fixed assets
Group
Goodwill
Software
Customer contracts
Licences
Total
£
£
£
£
£
Cost
At 1 January 2022
3,560,426
1,229,651
1,234,498
995
6,025,570
Additions
-
0
378,629
-
0
-
0
378,629
Revaluation
-
0
-
0
(726,194)
-
0
(726,194)
At 31 December 2022
3,560,426
1,608,280
508,304
995
5,678,005
Amortisation and impairment
At 1 January 2022
1,202,730
11,861
630,626
-
0
1,845,217
Amortisation charged for the year
356,447
-
0
177,746
-
0
534,193
Impairment losses
-
0
1,596,419
-
0
-
0
1,596,419
Eliminated on revaluation
-
0
-
0
(438,670)
-
0
(438,670)
At 31 December 2022
1,559,177
1,608,280
369,702
-
0
3,537,159
Carrying amount
At 31 December 2022
2,001,249
-
0
138,602
995
2,140,846
At 31 December 2021
2,357,696
1,217,790
603,872
995
4,180,353
The company had no intangible fixed assets at 31 December 2022 or 31 December 2021.

More information on impairment movements in the year is given in note 11.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022
- 33 -
14
Fixed asset investments
Group
Company
2022
2021
2022
2021
Notes
£
£
£
£
Investments in subsidiaries
15
-
0
-
0
6,550,364
6,597,894
Movements in fixed asset investments
Company
Shares in subsidiaries
£
Cost or valuation
At 1 January 2022
6,597,894
Additions
992,668
Valuation changes
(500,000)
Impairment
(540,198)
At 31 December 2022
6,550,364
Carrying amount
At 31 December 2022
6,550,364
At 31 December 2021
6,597,894
KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022
- 34 -
15
Subsidiaries

Details of the company's subsidiaries at 31 December 2022 are as follows:

Name of undertaking
Reg
Nature of business
Class of
% Held
office
shares
Direct
Indirect
Insurance Medical Reporting Services Limited
B
Dormant
Ordinary
100.00
-
Kuro Rehabilitation Services Limited
B
Dormant
Ordinary
100.00
-
Medicals Direct Group Limited
A
Dormant
Ordinary
0
100.00
Medicals Direct Healthcare Limited
A
Dormant
Ordinary
0
100.00
Medicals Direct Holdings Limited
A
Dormant
Ordinary
0
100.00
Medicals Direct Screenings Limited
A
Medical Screening Services
Ordinary
100.00
-
Medicals Direct Screenings Services Limited
A
Medical Screening Services
Ordinary
0
100.00
Rehab-Link Limited
C
Medical Rehabilitation Services
Ordinary
100.00
-
Premier Medical Group Limited
B
Medical Reporting Services
Ordinary
100.00
-
Kuro Health Services Limited
A
Medical Services
Ordinary
100.00
-
South East Specialist Medical Reports Limited
D
Medical Reporting Services
Ordinary
100.00
-
WARP Medical Reporting Limited
A
Dormant
Ordinary
0
100.00
WARP Technologies Limited
A
Software Consultancy
Ordinary
100.00
-
Medchi Limited
A
Dormant
Ordinary
0
100.00
Medical Specialist Reporting Group Limited
A
Dormant
Ordinary
0
100.00
Mobile Doctors Limited
D
Medical Services
Ordinary
100.00
-

Registered office:

A - 4th Floor, Park Gate, 161-163 Preston Road, Brighton, East Sussex, England. BN1 6AF
B - Premier House, Eco Park Road, Ludlow, Shropshire, England. SY8 1ES
C - Palatine House, Belmont Business Park, Durham, England. DH1 1TW

D - Unit 4 The Courtyard, Calvin Street, Bolton, England. BL1 8PB

KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022
- 35 -
16
Debtors
Group
Company
2022
2021
2022
2021
as restated
Amounts falling due within one year:
£
£
£
£
Trade debtors
58,177,261
48,982,507
-
0
-
0
Amounts owed by group undertakings
-
-
10,341,412
10,241,665
Other debtors
138,959
264,670
-
0
-
0
Prepayments and accrued income
3,427,587
3,174,253
27,131
7,989
61,743,807
52,421,430
10,368,543
10,249,654
Amounts falling due after more than one year:
Deferred tax asset (note 21)
50,355
6,017
-
0
-
0
Total debtors
61,794,162
52,427,447
10,368,543
10,249,654
17
Creditors: amounts falling due within one year
Group
Company
2022
2021
2022
2021
as restated
Notes
£
£
£
£
Bank loans and lD facility
19
15,376,625
13,498,105
-
0
-
0
Trade creditors
10,606,889
9,022,605
32,356
7,248
Amounts due to group undertakings
-
0
-
0
1,236,491
627,262
Corporation tax payable
344,156
296,968
-
0
-
0
Other taxation and social security
10,131,542
8,477,962
17,521
25,105
Deferred income
5,000
936
-
0
-
0
Other creditors
1,172,535
878,228
775,723
645,007
Accruals
5,013,185
3,277,191
256,593
91,565
42,649,932
35,451,995
2,318,684
1,396,187
18
Creditors: amounts falling due after more than one year
Group
Company
2022
2021
2022
2021
Notes
£
£
£
£
Bank loans and overdrafts
19
1,460,336
1,575,000
-
0
-
0
Other borrowings
19
1,175,000
1,175,000
1,175,000
1,175,000
2,635,336
2,750,000
1,175,000
1,175,000
KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022
- 36 -
19
Loans and overdrafts
Group
Company
2022
2021
2022
2021
£
£
£
£
Bank loans
1,898,437
2,025,000
-
0
-
0
Bank overdrafts
14,938,524
13,048,105
-
0
-
0
Preference shares
1,175,000
1,175,000
1,175,000
1,175,000
18,011,961
16,248,105
1,175,000
1,175,000
Payable within one year
15,376,625
13,498,105
-
0
-
0
Payable after one year
2,635,336
2,750,000
1,175,000
1,175,000

The group's finance facilities are provided by Barclays Bank PLC. The group has access to an invoice discount facility line of £15,275,000, an overdraft facility of £500,000, and a CBILS loan. As at 31 December 2022 the outstanding balance due to Barclays Bank PLC in respect of these facilities was £16,836,961 (31 December 2021: £15,073,105).

 

The facility is secured by a fixed and floating charge over current and future assets of various subsidiary companies.

20
Provisions for liabilities
Group
Company
2022
2021
2022
2021
£
£
£
£
Dilapidations
178,500
309,100
-
-
Movements on provisions:
Dilapidations
Group
£
At 1 January 2022
309,100
Utilisation of provision
(130,600)
At 31 December 2022
178,500

The provisions for dilapidations are in respect of leases on properties occupied by the group. The group has five leases of varying lengths and optional break clauses. The senior management team assess the provisions with advice from qualified professionals where appropriate.

KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022
- 37 -
21
Deferred taxation

Deferred tax assets and liabilities are offset where the group or company has a legally enforceable right to do so. The following is the analysis of the deferred tax balances (after offset) for financial reporting purposes:

Assets
Assets
2022
2021
Group
£
£
Accelerated capital allowances
24,480
(27,206)
Retirement benefit obligations
-
1,873
Provisions
25,875
31,350
50,355
6,017
The company has no deferred tax assets or liabilities.
Group
Company
2022
2022
Movements in the year:
£
£
Asset at 1 January 2022
6,017
-
Charge to profit or loss
44,338
-
Asset at 31 December 2022
50,355
-
22
Retirement benefit schemes
2022
2021
Defined contribution schemes
£
£
Charge to profit or loss in respect of defined contribution schemes
459,452
407,790

 

 

 

 

 

 

 

 

KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022
- 38 -
23
Share capital
2022
2021
2022
2021
Ordinary share capital
Number
Number
£
£
Issued and fully paid
as restated
as restated
B ordinary of £1 each
741
741
741
741
C ordinary of £1 each
40
40
40
40
D ordinary of £1 each
20
20
20
20
E ordinary of £1 each
826
826
826
826
F ordinary of £1 each
410
410
410
410
2,037
2,037
2,037
2,037
2022
2021
2022
2021
Preference share capital
Number
Number
£
£
Issued and fully paid
Redeemable preference shares of £1 each
1,175,000
1,175,000
1,175,000
1,175,000
Preference shares classified as liabilities
1,175,000
1,175,000

40 B ordinary shares were incorrectly designated as C ordinary shares in 2020.

 

The preference shares rank ahead of the ordinary share capital. An annual dividend of 12% of the subscription price paid is due on 31 December. There is no redemption date set for the preference shares.

 

All classes of ordinary shares rank equally for dividend and voting rights.

 

 

 

 

 

 

 

 

 

 

 

KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022
- 39 -
24
Operating lease commitments
Lessee

At the reporting end date the group had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

Group
Company
2022
2021
2022
2021
£
£
£
£
Within one year
210,222
395,139
-
-
Between two and five years
89,162
611,275
-
-
In over five years
-
62,755
-
-
299,384
1,069,169
-
-

The lease commitments are in respect of rental agreements for properties. In the prior year the group calculated its commitment excluding any contractual break clauses. Two break clauses have been enacted which represents the movement shown above.

25
Related party transactions

During the year the company made payments for consultancy and professional fees totalling £314,507 (31 December 2021: £461,965) to companies controlled or associated to the directors.

 

Folkington Finance Limited is a company controlled or associated to the directors, was owed £771,574 (31 December 2021: £141,000) as at 31 December 2022. During the year, it advanced £489,574 and accrued a preference dividend of £141,000 to the company.

 

No details are included for the transactions with subsidiaries that are 100% owned as the exemption for such companies is being claimed.

 

 

KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022
- 40 -
26
Cash absorbed by group operations
2022
2021
£
£
(Loss)/profit for the year after tax
(382,804)
1,186,529
Adjustments for:
Taxation (credited)/charged
(794)
179,809
Finance costs
818,360
459,742
Investment income
(161)
(97)
Goodwill deferred consideration no longer due
555,795
-
0
Amortisation and impairment of intangible assets
1,862,341
819,813
Depreciation and impairment of tangible fixed assets
206,465
189,744
(Decrease)/increase in provisions
(130,600)
20,100
Movements in working capital:
Increase in debtors
(9,322,377)
(4,005,556)
Increase/(decrease) in creditors
4,637,591
(1,101,148)
Increase in deferred income
4,064
17,793
Cash absorbed by operations
(1,752,120)
(2,233,271)
27
Analysis of changes in net debt - group
1 January 2022
Cash flows
31 December 2022
£
£
£
Cash at bank and in hand
895,104
(622,649)
272,455
Bank overdrafts
(13,048,105)
(1,890,419)
(14,938,524)
(12,153,001)
(2,513,068)
(14,666,069)
Borrowings excluding overdrafts
(3,200,000)
126,563
(3,073,437)
Other loans
-
(489,574)
(489,574)
(15,353,001)
(2,876,079)
(18,229,080)
28
Cross Guarantee

A cross guarantee was given by the group in favour of Barclays Bank PLC. The cross guarantee is in support of the finance facilities provided by Barclays Bank PLC to Kuro Health group of entities. The cross guarantee includes the following group companies: Kuro Health Limited, Premier Medical Group Limited, Rehab-Link Limited, South East Specialist Medical Reports Limited and Mobile Doctors Limited. The balance owed to Barclays Bank PLC at 31 December 2022 was £16,387,870 (31 December 2021: £15,073,106).

 

KURO HEALTH LIMITED AND SUBSIDIARY UNDERTAKINGS
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2022
- 41 -
29
Prior period adjustments

Descriptions of the effect of the prior period adjustments to the 2021 balance sheet and profit and loss are set out below.

 

The opening balances of assets and liabilities have been restated by £80,169. Overall there was no effect in the consolidated net current assets as at the 31 December 2021. 

 

Also restated was turnover (decrease of £80,170), direct costs (increase of £1,060,008) and administrative expenses (decrease of £1,140,178). Overall there was no effect in the consolidated profit for the year ended 31 December 2021. The prior year adjustment is predominantly to reclassify the split of salaries between direct costs and administrative costs from the subsidiary acquired in the prior year.

 

The prior period adjustments did not give rise to any effect upon equity.

2022-12-312022-01-01falseCCH SoftwareCCH Accounts Production 2023.200Dr H O BrunjesMr T AspinallMrs J M BrunjesDr R C GoodallMr B GrayMr G J Sampson09941789bus:Consolidated2022-01-012022-12-31099417892022-01-012022-12-3109941789bus:Director12022-01-012022-12-3109941789bus:Consolidated2022-12-31099417892022-12-3109941789bus:Consolidated2021-01-012021-12-3109941789core:Goodwillbus:Consolidated2022-12-3109941789core:Goodwillbus:Consolidated2021-12-3109941789core:ComputerSoftwarebus:Consolidated2022-12-3109941789core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwillbus:Consolidated2022-12-3109941789core:Non-standardIntangibleAssetClass2ComponentIntangibleAssetsOtherThanGoodwillbus:Consolidated2022-12-3109941789core:ComputerSoftwarebus:Consolidated2021-12-3109941789core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwillbus:Consolidated2021-12-3109941789core:Non-standardIntangibleAssetClass2ComponentIntangibleAssetsOtherThanGoodwillbus:Consolidated2021-12-3109941789bus:Consolidated2021-12-3109941789core:LeaseholdImprovementsbus:Consolidated2022-12-3109941789core:FurnitureFittingsbus:Consolidated2022-12-3109941789core:ComputerEquipmentbus:Consolidated2022-12-3109941789core:LeaseholdImprovementsbus:Consolidated2021-12-3109941789core:FurnitureFittingsbus:Consolidated2021-12-3109941789core:ComputerEquipmentbus:Consolidated2021-12-3109941789core:ShareCapitalbus:Consolidated2022-12-3109941789core:ShareCapitalbus:Consolidated2021-12-3109941789core:CapitalRedemptionReservebus:Consolidated2022-12-3109941789core:CapitalRedemptionReservebus:Consolidated2021-12-3109941789core:ShareCapital2022-12-3109941789core:ShareCapital2021-12-3109941789core:CapitalRedemptionReserve2022-12-3109941789core:CapitalRedemptionReserve2021-12-3109941789core:RetainedEarningsAccumulatedLosses2022-12-3109941789core:ShareCapitalbus:Consolidated2020-12-3109941789core:CapitalRedemptionReservebus:Consolidated2020-12-3109941789core:RetainedEarningsAccumulatedLossesbus:Consolidated2020-12-3109941789core:RetainedEarningsAccumulatedLossesbus:Consolidated2021-12-3109941789core:RetainedEarningsAccumulatedLossesbus:Consolidated2022-12-3109941789core:ShareCapital2020-12-3109941789core:CapitalRedemptionReserve2020-12-3109941789core:RetainedEarningsAccumulatedLosses2020-12-3109941789core:RetainedEarningsAccumulatedLosses2021-12-31099417892021-12-3109941789bus:Consolidated2020-12-3109941789core:Goodwill2022-01-012022-12-3109941789core:IntangibleAssetsOtherThanGoodwill2022-01-012022-12-3109941789core:ComputerSoftware2022-01-012022-12-3109941789core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2022-01-012022-12-3109941789core:Non-standardIntangibleAssetClass2ComponentIntangibleAssetsOtherThanGoodwill2022-01-012022-12-3109941789core:LandBuildingscore:LongLeaseholdAssets2022-01-012022-12-3109941789core:LeaseholdImprovements2022-01-012022-12-3109941789core:FurnitureFittings2022-01-012022-12-3109941789core:ComputerEquipment2022-01-012022-12-3109941789core:ConstructionInProgressAssetsUnderConstruction2022-01-012022-12-31099417892021-01-012021-12-3109941789core:UKTaxbus:Consolidated2022-01-012022-12-3109941789core:UKTaxbus:Consolidated2021-01-012021-12-3109941789bus:Consolidated12022-01-012022-12-3109941789bus:Consolidated12021-01-012021-12-3109941789bus:Consolidated22022-01-012022-12-3109941789bus:Consolidated22021-01-012021-12-3109941789bus:Consolidated32022-01-012022-12-3109941789bus:Consolidated32021-01-012021-12-3109941789bus:Consolidated42022-01-012022-12-3109941789bus:Consolidated42021-01-012021-12-3109941789bus:Consolidated52022-01-012022-12-3109941789bus:Consolidated52021-01-012021-12-3109941789core:LeaseholdImprovementsbus:Consolidated2021-12-3109941789core:FurnitureFittingsbus:Consolidated2021-12-3109941789core:ComputerEquipmentbus:Consolidated2021-12-3109941789bus:Consolidated2021-12-3109941789core:LeaseholdImprovementsbus:Consolidated2022-01-012022-12-3109941789core:FurnitureFittingsbus:Consolidated2022-01-012022-12-3109941789core:ComputerEquipmentbus:Consolidated2022-01-012022-12-3109941789core:Goodwillbus:Consolidated2021-12-3109941789core:ComputerSoftwarebus:Consolidated2021-12-3109941789core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwillbus:Consolidated2021-12-3109941789core:Non-standardIntangibleAssetClass2ComponentIntangibleAssetsOtherThanGoodwillbus:Consolidated2021-12-3109941789core:Goodwillcore:ExternallyAcquiredIntangibleAssetsbus:Consolidated2022-01-012022-12-3109941789core:ComputerSoftwarecore:ExternallyAcquiredIntangibleAssetsbus:Consolidated2022-01-012022-12-3109941789core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwillcore:ExternallyAcquiredIntangibleAssetsbus:Consolidated2022-01-012022-12-3109941789core:Non-standardIntangibleAssetClass2ComponentIntangibleAssetsOtherThanGoodwillcore:ExternallyAcquiredIntangibleAssetsbus:Consolidated2022-01-012022-12-3109941789core:ExternallyAcquiredIntangibleAssetsbus:Consolidated2022-01-012022-12-3109941789core:ComputerSoftwarebus:Consolidated2022-01-012022-12-3109941789core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwillbus:Consolidated2022-01-012022-12-3109941789core:Non-standardIntangibleAssetClass2ComponentIntangibleAssetsOtherThanGoodwillbus:Consolidated2022-01-012022-12-3109941789core:Goodwillbus:Consolidated2022-01-012022-12-3109941789core:Subsidiary12022-01-012022-12-3109941789core:Subsidiary22022-01-012022-12-3109941789core:Subsidiary32022-01-012022-12-3109941789core:Subsidiary42022-01-012022-12-3109941789core:Subsidiary52022-01-012022-12-3109941789core:Subsidiary62022-01-012022-12-3109941789core:Subsidiary72022-01-012022-12-3109941789core:Subsidiary82022-01-012022-12-3109941789core:Subsidiary92022-01-012022-12-3109941789core:Subsidiary102022-01-012022-12-3109941789core:Subsidiary112022-01-012022-12-3109941789core:Subsidiary122022-01-012022-12-3109941789core:Subsidiary132022-01-012022-12-3109941789core:Subsidiary142022-01-012022-12-3109941789core:Subsidiary152022-01-012022-12-3109941789core:Subsidiary162022-01-012022-12-310994178912022-01-012022-12-310994178922022-01-012022-12-310994178932022-01-012022-12-310994178942022-01-012022-12-310994178952022-01-012022-12-310994178962022-01-012022-12-310994178972022-01-012022-12-310994178982022-01-012022-12-310994178992022-01-012022-12-3109941789102022-01-012022-12-3109941789112022-01-012022-12-3109941789122022-01-012022-12-3109941789132022-01-012022-12-3109941789142022-01-012022-12-3109941789152022-01-012022-12-3109941789162022-01-012022-12-3109941789core:Subsidiary112022-01-012022-12-3109941789core:Subsidiary222022-01-012022-12-3109941789core:Subsidiary332022-01-012022-12-3109941789core:Subsidiary442022-01-012022-12-3109941789core:Subsidiary552022-01-012022-12-3109941789core:Subsidiary662022-01-012022-12-3109941789core:Subsidiary772022-01-012022-12-3109941789core:Subsidiary882022-01-012022-12-3109941789core:Subsidiary992022-01-012022-12-3109941789core:Subsidiary10102022-01-012022-12-3109941789core:Subsidiary11112022-01-012022-12-3109941789core:Subsidiary12122022-01-012022-12-3109941789core:Subsidiary13132022-01-012022-12-3109941789core:Subsidiary14142022-01-012022-12-3109941789core:Subsidiary15152022-01-012022-12-3109941789core:Subsidiary16162022-01-012022-12-3109941789core:CurrentFinancialInstruments2022-12-3109941789core:CurrentFinancialInstruments2021-12-3109941789core:CurrentFinancialInstrumentsbus:Consolidated2022-12-3109941789core:CurrentFinancialInstrumentsbus:Consolidated2021-12-3109941789core:Non-currentFinancialInstrumentsbus:Consolidated2022-12-3109941789core:Non-currentFinancialInstrumentsbus:Consolidated2021-12-3109941789core:Non-currentFinancialInstruments2022-12-3109941789core:Non-currentFinancialInstruments2021-12-3109941789core:WithinOneYearbus:Consolidated2022-12-3109941789core:WithinOneYearbus:Consolidated2021-12-3109941789core:CurrentFinancialInstrumentscore:WithinOneYear2022-12-3109941789core:CurrentFinancialInstrumentscore:WithinOneYear2021-12-3109941789core:Non-currentFinancialInstrumentscore:AfterOneYearbus:Consolidated2022-12-3109941789core:Non-currentFinancialInstrumentscore:AfterOneYearbus:Consolidated2021-12-3109941789core:Non-currentFinancialInstrumentscore:AfterOneYear2022-12-3109941789core:Non-currentFinancialInstrumentscore:AfterOneYear2021-12-3109941789core:CurrentFinancialInstrumentscore:WithinOneYearbus:Consolidated2022-12-3109941789core:CurrentFinancialInstrumentscore:WithinOneYearbus:Consolidated2021-12-3109941789bus:PrivateLimitedCompanyLtd2022-01-012022-12-3109941789bus:FRS1022022-01-012022-12-3109941789bus:Audited2022-01-012022-12-3109941789bus:ConsolidatedGroupCompanyAccounts2022-01-012022-12-3109941789bus:Director22022-01-012022-12-3109941789bus:Director32022-01-012022-12-3109941789bus:Director42022-01-012022-12-3109941789bus:Director52022-01-012022-12-3109941789bus:Director62022-01-012022-12-3109941789bus:FullAccounts2022-01-012022-12-31xbrli:purexbrli:sharesiso4217:GBP